(AOF) – Following the approval of the Board of Directors, Léone Atayi, Chief Executive Officer of Hybrigenics SA will present on November 30, 2022 the strategic plan which aims to guide Hybrigenics’ strategy in the treatment value chain. therapies at the service of players in the pharmaceutical and biotechnology industries. The proposed separation with DMS Group is an opportunity for Hybrigenics to develop in its natural environment: the pharmaceutical industry and biotechnology.
In this dynamic ecosystem, Hybrigenics and its subsidiaries have the opportunity to occupy a central place thanks to the uniqueness of their technologies. This strategic plan will be structured in three phases, launched in parallel.
The “Renaissance” phase, which began at the end of 2021 and will extend until 2023, will focus on asserting a new identity to clearly identify the Hybrigenics group as a player in the pharmaceutical industry. and biotech, and on restoring growth and generating cash.
The “Transformation” phase, which will continue until 2025, will evolve Hybrigenics’ business model towards the synergistic integration of technologies, making the group a forerunner in the value chain for the development of therapeutic treatments.
The “Expansion” phase, which will begin in 2024, will see the group’s international deployment accelerate, helping to increase turnover.
This strategic plan will allow the Hybrigenics group to take advantage of the current technological advance of the companies that make it up; to increase the efficiency of its production processes in order to reduce fixed costs; improve profitability by pooling support functions allowing each company to focus on its customers and its markets; and attract new investors to increase its impact in terms of products and activities.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.